Why Affirm™ VPIII?

Vaginal infections affect virtually every woman at some point in life. Bacterial vaginosis, candidiasis and trichomoniasis — the three most prevalent vaginal infections — frequently occur as mixed infections, meaning that targeting only one pathogen leaves the underlying condition untreated and leads to recurrence.

Conventional diagnosis often relies on microscopic wet-mount examination, which is highly dependent on the skill and subjective judgment of the observer, and is vulnerable to sample instability during transport. Affirm™ VPIII addresses these limitations by using patented DNA probe technology to directly detect pathogen nucleic acids, providing objective, reproducible results unaffected by sample handling conditions or mixed infection interference.

How It Works

• Single vaginal swab sample collected at point of care
• DNA probe hybridisation directly targets pathogen nucleic acids
• Fully automated sample handling, processing and result reading
• Clear positive/negative results for each of the three pathogens
• Results unaffected by mixed infections, sample contamination or transport conditions

Clinical Benefits

• Eliminates misdiagnosis caused by single-pathogen testing
• Enables evidence-based, targeted treatment from first consultation
• Reduces recurrence rates by identifying mixed infection profiles
• Streamlines OB/GYN outpatient workflow with rapid, same-visit results